logo-loader
viewAvacta Group PLC

Avacta Group appoints Immunocore’s Eliot Forster as non-executive chairman

The AIM-listed firm said Dr Trevor Nichols, who has acted as chairman of the board since January 2014, will remain on the board as non-executive director

handshake
The company, which develops Affimer biotherapeutics and reagents, said Forster brings over 25 years of experience in the pharmaceutical and biotechnology industry

Avacta Group Plc (LON:AVCT) has announced the appointment of Dr Eliot Forster as non-executive chairman to the board with immediate effect.

The AIM-listed firm said Dr Trevor Nichols, who has acted as chairman of the board since January 2014, will remain on the board as non-executive director.

READ: Avacta hails encouraging results to tie-up with Finnish firm, shares gain

The company, which develops Affimer biotherapeutics and reagents, said Forster brings over 25 years of experience in the pharmaceutical and biotechnology industry.

Avacta said most recently he led Immunocore as chief executive officer to become a world-leading immuno-oncology biotech, raising over £230mln in equity and non-dilutive funding as well as securing partnerships with AstraZeneca PLC (LON:AZN) and the Bill & Melinda Gates Foundation.

The early part of Forster's career was at GSK and then he went on to hold a number of senior roles in Pfizer Inc (NYSE:PFE)

Alastair Smith, CEO of Avacta Group, said: “We have an exciting opportunity to build a world-leading and highly valuable biotech based on the Affimer platform.”

He added: ”Eliot's considerable experience, expertise and network will make a material difference to achieving that goal and to delivering maximum value to shareholders.”

Quick facts: Avacta Group PLC

Price: 16.5 GBX

AIM:AVCT
Market: AIM
Market Cap: £19.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Plc's therapeutics business 'has huge amount of potential' - analyst...

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space. The group's reported interim results to January 2019 today, revealing revenues of...

on 9/4/19

2 min read